BIOMAT Database Logo BIOMAT Database Logo

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. 2018

E David Crawford, and B Tombal, and T Keane, and F Boccardo, and K Miller, and N Shore, and J W Moul, and J-E Damber, and L Collette, and B-E Persson
a Division of Urology , University of Colorado , Aurora , CO , USA.

BACKGROUND Gonadotropin releasing hormone (GnRH) antagonists suppress follicle-stimulating hormone (FSH) to lower levels than GnRH agonists. This may partially explain the differences between these agents on prostate cancer outcomes. In this post-hoc analysis, FSH and prostate specific antigen (PSA) responses and the impact of cross-over from leuprolide to degarelix were evaluated from a 1-year comparative study (CS21) and its extension study (CS21A). METHODS Overall, 610 patients were enrolled in CS21, wherein PSA and FSH levels were evaluated monthly. CS21A evaluated 386 patients, including those previously treated with degarelix (n = 251) who continued to receive degarelix, and those previously treated with leuprolide (n = 135) who crossed-over to receive degarelix. PSA and FSH levels were evaluated in CS21A for 3 months after cross-over. The associations between measurements were assessed using Spearman's correlation coefficient. The impact of class variables on FSH suppression were evaluated using Analysis of Variance. RESULTS Rapid PSA and FSH suppression was observed and maintained in the degarelix arm (CS21 and CS21A), while patients on leuprolide experienced rising PSA during CS21. Patients crossed-over from leuprolide to degarelix achieved a suppression of FSH and a significant PSA decrease. PSA and FSH levels were significantly (p < .05) correlated at months 1, 3, 6, 12 and 13 in the degarelix arm. CONCLUSIONS Significant FSH suppression with GnRH antagonists may explain its advantage over GnRH agonists in terms of better prostate cancer control. The effect of profound FSH suppression is analogous to the need for profound testosterone suppression for tumor control.

UI MeSH Term Description Entries
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D007987 Gonadotropin-Releasing Hormone A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND. FSH-Releasing Hormone,GnRH,Gonadoliberin,Gonadorelin,LH-FSH Releasing Hormone,LHRH,Luliberin,Luteinizing Hormone-Releasing Hormone,Cystorelin,Dirigestran,Factrel,Gn-RH,Gonadorelin Acetate,Gonadorelin Hydrochloride,Kryptocur,LFRH,LH-RH,LH-Releasing Hormone,LHFSH Releasing Hormone,LHFSHRH,FSH Releasing Hormone,Gonadotropin Releasing Hormone,LH FSH Releasing Hormone,LH Releasing Hormone,Luteinizing Hormone Releasing Hormone,Releasing Hormone, LHFSH
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D005640 Follicle Stimulating Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. FSH (Follicle Stimulating Hormone),Follicle-Stimulating Hormone,Follitropin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D016729 Leuprolide A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. Leuprorelin,A-43818,Enantone,Leuprolide Acetate,Leuprolide Monoacetate,Leuprolide, (DL-Leu)-Isomer,Leuprolide, (L-Leu)-Isomer,Lupron,TAP-144,A 43818,A43818,Acetate, Leuprolide,Monoacetate, Leuprolide,TAP 144,TAP144

Related Publications

E David Crawford, and B Tombal, and T Keane, and F Boccardo, and K Miller, and N Shore, and J W Moul, and J-E Damber, and L Collette, and B-E Persson
Switching Patients With Prostate Cancer from GnRH Antagonist to Long-acting LHRH Agonist for Androgen Deprivation: Reducing Hospital Visits During the Coronavirus Pandemic.
January 2021, Cancer diagnosis & prognosis,
E David Crawford, and B Tombal, and T Keane, and F Boccardo, and K Miller, and N Shore, and J W Moul, and J-E Damber, and L Collette, and B-E Persson
A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
September 2016, BMC cancer,
E David Crawford, and B Tombal, and T Keane, and F Boccardo, and K Miller, and N Shore, and J W Moul, and J-E Damber, and L Collette, and B-E Persson
Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist.
August 2015, Cancer chemotherapy and pharmacology,
E David Crawford, and B Tombal, and T Keane, and F Boccardo, and K Miller, and N Shore, and J W Moul, and J-E Damber, and L Collette, and B-E Persson
Oral GnRH Antagonist Ovarian Suppression After Escape From GnRH Agonist in Breast Cancer Patients.
October 2020, Clinical breast cancer,
E David Crawford, and B Tombal, and T Keane, and F Boccardo, and K Miller, and N Shore, and J W Moul, and J-E Damber, and L Collette, and B-E Persson
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
August 2015, World journal of urology,
E David Crawford, and B Tombal, and T Keane, and F Boccardo, and K Miller, and N Shore, and J W Moul, and J-E Damber, and L Collette, and B-E Persson
Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin.
October 2001, Urology,
E David Crawford, and B Tombal, and T Keane, and F Boccardo, and K Miller, and N Shore, and J W Moul, and J-E Damber, and L Collette, and B-E Persson
A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control.
January 2019, Case reports in oncology,
E David Crawford, and B Tombal, and T Keane, and F Boccardo, and K Miller, and N Shore, and J W Moul, and J-E Damber, and L Collette, and B-E Persson
Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
January 2018, International journal of urology : official journal of the Japanese Urological Association,
E David Crawford, and B Tombal, and T Keane, and F Boccardo, and K Miller, and N Shore, and J W Moul, and J-E Damber, and L Collette, and B-E Persson
Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist.
January 2015, Basic and clinical andrology,
E David Crawford, and B Tombal, and T Keane, and F Boccardo, and K Miller, and N Shore, and J W Moul, and J-E Damber, and L Collette, and B-E Persson
GNRH-agonist or antagonist in the treatment of prostate cancer: a comparision based on oncological results.
November 2016, Urologia,
Copied contents to your clipboard!